021-51111890
购物车（）
sales@molnova.cn
Elesclomol
CAS No. 488832-69-5
Elesclomol ( STA-4783 | STA4783 | STA 4783 )
产品货号. M14641 CAS No. 488832-69-5
Elesclomol (STA-4783) 是一种小分子氧化应激诱导剂。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥275 | 有现货 |
|
| 10MG | ￥478 | 有现货 |
|
| 25MG | ￥761 | 有现货 |
|
| 50MG | ￥1037 | 有现货 |
|
| 100MG | ￥1320 | 有现货 |
|
| 200MG | ￥1968 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Elesclomol
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Elesclomol (STA-4783) 是一种小分子氧化应激诱导剂。
-
产品描述Elesclomol (STA-4783) is a small-molecule oxidative stress inducer, exerts selective cytotoxicity by increasing intracellular concentrations of reactive oxygen species (ROS) and induces cell death via mitochondrial apoptosisin cancer cells; selectively kills cisplatin-resistant tumor cells through increased ROS, markedly enhances the therapeutic index of paclitaxel against human tumor xenograft models. Ovarian Cancer Phase 2 Clinical.
-
体外实验Apoptosis AnalysisCell Line:HSB2 cells Concentration:200 nM Incubation Time:18 hours Result:Increased the number of early and late apoptotic cells.
-
体内实验Animal Model:Cardiac Ctr1 knockout mice Dosage:10 mg/kg Administration:Subcutaneous injection; every three days from post-natal day 5 to 26 and once weekly until post-natal day 54 Result:Ameliorated severe cardiac pathology with a partial reduction in hypertrophy.
-
同义词STA-4783 | STA4783 | STA 4783
-
通路Apoptosis
-
靶点Apoptosis
-
受体HSP70
-
研究领域Cancer
-
适应症Ovarian Cancer
化学信息
-
CAS Number488832-69-5
-
分子量400.5177
-
分子式C19H20N4O2S2
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 22 mg/mL
-
SMILESO=C(NN(C)C(C1=CC=CC=C1)=S)CC(NN(C)C(C2=CC=CC=C2)=S)=O
-
化学全称Propanedioic acid, 1,3-bis[2-methyl-2-(phenylthioxomethyl)hydrazide]
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Berkenblit A, et al. Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):584-90.
2. Kirshner JR, et al. Mol Cancer Ther. 2008 Aug;7(8):2319-27.
3. Wangpaichitr M, et al. Cancers (Basel). 2009;1(1):23-38.
4. Kluza J, et al. Cancer Res. 2012 Oct 1;72(19):5035-47.
产品手册
关联产品
-
CDK8-IN-13
CDK8-IN-13 is a potent, selective and orally active CDK8 inhibitor with an IC50 value of 51.9 nM. CDK8-IN-13 induces Apoptosis. CDK8-IN-13 decreases the expression of p-STAT1 S727 and p-STAT5 S726. CDK8-IN-13 shows antitumor activity.
-
Zoledronic acid mono...
唑来膦酸水合物是一种合成的咪唑二膦酸盐类似物，具有抗骨吸收活性。
-
Tubulin polymerizati...
Tubulin polymerization-IN-43 (compound 15h) 是一种微管蛋白聚合 (tubulin polymerization) 抑制剂。Tubulin polymerization-IN-43 通过靶向 Colchicine (HY-16569) 位点破坏细胞微管网络，促进白血病细胞的细胞周期停滞在 G2/M 期和细胞凋亡 (apoptosis)，并抑制血管生成。
